Evaluating darunavir/ritonavir dosing regimens for HIV-positive pregnant women using semi-mechanistic pharmacokinetic modelling-Reference-Cited by-同舟云学术

Evaluating darunavir/ritonavir dosing regimens for HIV-positive pregnant women using semi-mechanistic pharmacokinetic modelling

Published:2019-01-30 Issue:5 Volume:74 Page:1348-1356
ISSN:0305-7453
Container-title:Journal of Antimicrobial Chemotherapy
language:en
Short-container-title:

Author:

Schalkwijk Stein¹²,ter Heine Rob¹,Colbers Angela¹,Capparelli Edmund³,Best Brookie M³,Cressey Tim R⁴⁵⁶,Greupink Rick²,Russel Frans G M²,Moltó José⁷⁸⁹,Mirochnick Mark¹⁰,Karlsson Mats O¹¹,Burger David M¹

Affiliation:

1. Department of Pharmacy, Radboud Institute for Health Sciences (RIHS), Radboud university medical center, Nijmegen, The Netherlands

2. Department of Pharmacology & Toxicology, Radboud Institute for Molecular Life Sciences (RIMLS), Radboud university medical center, Nijmegen, The Netherlands

3. Skaggs School of Pharmacy and Pharmaceutical Sciences & School of Medicine, University of California San Diego, San Diego, CA, USA

4. Faculty of Associated Medical Sciences, Chiang Mai University, Chiang Mai, Thailand

5. Harvard T.H. Chan School of Public Health, Boston, MA, USA

6. Department of Molecular & Clinical Pharmacology, University of Liverpool, Liverpool, UK

7. Fundació Lluita contra la Sida, Hospital Universitari Germans Trias i Pujol, Badalona, Spain

8. Infectious Diseases Department, Hospital Universitari Germans Trias i Pujol, Badalona, Spain

9. Universitat Autònoma de Barcelona (UAB), Barcelona, Spain

10. Department of Pediatrics, Boston University School of Medicine, Boston, MA, USA

11. Department of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden

Funder

National Institute of Allergy and Infectious Diseases

National Institutes of Health

National Institute of Child Health and Human Development

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology,Microbiology (medical)

Link

http://academic.oup.com/jac/article-pdf/74/5/1348/28501273/dky567.pdf

Reference35 articles.

1. Antiretroviral pharmacokinetics in pregnant women;Gilbert;Pharmacotherapy,2015

2. Use of enhanced perinatal human immunodeficiency virus surveillance methods to assess antiretroviral use and perinatal human immunodeficiency virus transmission in the United States, 1999–2001;Harris;Am J Obstet Gynecol,2007

3. Earlier initiation of ART and further decline in mother-to-child HIV transmission rates, 2000–2011;Townsend;AIDS,2014

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Directive clinique no 450 : Prise en charge des femmes enceintes vivant avec le VIH et interventions pour réduire le risque de transmission périnatale;Journal of Obstetrics and Gynaecology Canada;2024-06

2. Guideline No. 450: Care of Pregnant Women Living with HIV and Interventions to Reduce Perinatal Transmission;Journal of Obstetrics and Gynaecology Canada;2024-06

3. Simultaneous pharmacokinetic modeling of unbound and total darunavir with ritonavir in adolescents: a substudy of the SMILE trial;Antimicrobial Agents and Chemotherapy;2023-12-11

4. A systematic review of pregnancy-related clinical intervention of drug regimens due to pharmacokinetic reasons;Frontiers in Medicine;2023-11-29

5. Daily ritonavir‐boosted darunavir for viral suppression in pregnancy (DRV‐P);HIV Medicine;2023-10-10